The video above is from Tuesday's MarketFoolery podcast, featuring host Chris Hill and analysts Joe Magyer and Bill Mann. In this segment, the guys look at Johnson & Johnson's (NYS: JNJ) latest earnings report, which turned out better than expected thanks to prescription drug sales and JNJ's medical device division. They also discuss why the company's growth opportunity in China is stronger than people may think.
If you're looking for some additional ideas or insights on your quest for high-yielding stocks, The Motley Fool has compiled a special free report outlining our top nine dependable dividend-paying companies. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks," and you can access your complimentary copy today at no cost. Simply click here now to get started and discover the winners we've selected.
The article Johnson & Johnson's Surprising Opportunity originally appeared on Fool.com.
Bill Mann has no positions in the stocks mentioned above. Chris Hill owns shares of Johnson & Johnson. Joe Magyer owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.